Treatment options for patients with mantle cell lymphoma post-transplantation: A scoping review of the literature

Abstract Mantle cell lymphoma is a rare subtype of B-cell lymphoma which carries with it a poor prognosis and is typically refractory to treatment. Autologous stem cell transplant (ASCT) has been shown to improve survival, but is not considered curative. There is currently no specific preferred regimen of treatment according to current guidelines for patients who fail ASCT. We undertook a systematic scoping review to examine the existing literature in this setting. A total of 3045 records were screened, yielding 40 full-text articles, 12 of which were included in the results. Ibrutinib and venetoclax appeared to produce the highest response rates and length of progression-free survival post-ASCT, however, there are serious gaps in the literature regarding what is actually known about the efficacy of treatment regiments for relapsed/refractory mantle cell lymphoma in post-ASCT patients and more randomized, controlled clinical trials are needed in this area.